> Chemicals & Drugs > Organic Chemical > Anthracyclines

Anthracyclines

Anthracyclines are a class of chemotherapeutic agents derived from the bacterium Streptomyces peucetius.
These potent anti-cancer drugs work by intercalating into DNA and inhibiting topoisomerase II, leading to cell death.
Anthracyclines are commonly used to treat a wide range of cancers, including leukemia, lymphoma, and solid tumors.
However, their use can be limited by the risk of serious side effects, such as cardiotoxicity.
Researchers can leverrage PubCompare.ai to streamline anthracycline research, easily locate protocols, and optimize thier studies through AI-powered comparisons.

Most cited protocols related to «Anthracyclines»

Predicting Sensitivity to Breast Cancer Therapy

Cited 57 times

We combined the individual predictions into a testing algorithm for predicted sensitivity to adjuvant treatment of HER2-negative breast cancer with taxane-anthracycline chemotherapy: 1) sensitivity to endocrine therapy assessed based on an independently validated 165-gene index of endocrine sensitivity (high or intermediate SET index)^{21 (link)}; 2) resistance to chemotherapy predicted either by early distant relapse events or by extensive residual disease after neoadjuvant chemotherapy; and 3) sensitivity (pathologic response) to chemotherapy (Figure 1). Additional methodological details are provided in the Supplemental Appendix.

Hatzis C., Pusztai L., Valero V., Booser D.J., Esserman L., Lluch A., Vidaurre T., Holmes F., Souchon E., Martin M., Cotrina J., Gomez H., Hubbard R., Chacón J.I., Ferrer-Lozano J., Dyer R., Buxton M., Gong Y., Wu Y., Ibrahim N., Andreopoulou E., Ueno N.T., Hunt K., Yang W., Nazario A., DeMichele A., O’Shaughnessy J., Hortobagyi G.N, & Symmans W.F. (2011). GENOMIC PREDICTOR OF RESPONSE AND SURVIVAL FOLLOWING TAXANE-ANTHRACYCLINE CHEMOTHERAPY FOR INVASIVE BREAST CANCER. JAMA, 305(18), 1873-1881.

Publication 2011

Anthracyclines erbb2 Gene Genes Hypersensitivity Malignant Neoplasm of Breast Neoadjuvant Chemotherapy Pharmaceutical Adjuvants Pharmacotherapy Relapse Residual Tumor System, Endocrine taxane Therapeutics

Neoadjuvant Chemotherapy for Invasive Breast Cancer

Cited 23 times

The I-SPY 1 TRIAL methods have been described in detail elsewhere [13 , 14 ] and was a collaboration of the American College of Radiology Imaging Network (ACRIN), Cancer and Leukemia Group B (CALGB), and Specialized programs of research excellence (SPORE). All patients gave written consent and had histologically confirmed invasive breast cancers measuring at least 3 cm by clinical examination or imaging, with no evidence of distant metastatic disease. Patients’ clinical stage 1 by exam was eligible if tumor size was >3 cm by imaging. Patients with T4 or inflammatory disease were eligible. The regimen of neoadjuvant chemotherapy included an initial anthracycline-based regimen after which patients either underwent surgery or received a taxane-based regimen prior to surgery.
Assays were conducted in nine laboratories. Data was integrated for central accession for analysis using NCICB’s caINTEGRATOR application (https://caintegrator-stage.nci.nih.gov/ispy/index2.jsp)—I-SPY 1 data version dated February 2011.

Esserman L.J., Berry D.A., Cheang M.C., Yau C., Perou C.M., Carey L., DeMichele A., Gray J.W., Conway-Dorsey K., Lenburg M.E., Buxton M.B., Davis S.E., van’t Veer L.J., Hudis C., Chin K., Wolf D., Krontiras H., Montgomery L., Tripathy D., Lehman C., Liu M.C., Olopade O.I., Rugo H.S., Carpenter J.T., Livasy C., Dressler L., Chhieng D., Singh B., Mies C., Rabban J., Chen Y.Y., Giri D., Au A, & Hylton N. (2011). Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment, 132(3), 1049-1062.

Publication 2011

Anthracyclines Biological Assay Inflammation Leukemia Malignant Neoplasm of Breast Malignant Neoplasms Neoadjuvant Chemotherapy Neoplasm Metastasis Neoplasms Operative Surgical Procedures Patients Physical Examination taxane Treatment Protocols X-Rays, Diagnostic

Diffuse Large-B-Cell Lymphoma Treatment Protocol

Cited 18 times

Pretreatment tumor-biopsy specimens and clinical data were obtained from 414 patients with newly diagnosed diffuse large-B-cell lymphoma who were treated at 10 institutions in North America and Europe and studied according to a protocol approved by the institutional review board of the National Cancer Institute. Among these patients, a CHOP training group consisted of 181 patients, previously described,^{4 (link)} who were treated with anthracycline-based combinations, most often CHOP or similar regimens. The other 233 patients constituted an R-CHOP cohort that received similar chemotherapy plus rituximab. The median follow-up for the R-CHOP cohort was 2.1 years; the median follow-up for survivors was 2.8 years. A panel of expert hematopathologists confirmed the diagnosis of diffuse large-B-cell lymphoma using current World Health Organization criteria. We also analyzed data from a second cohort of 177 patients who received CHOP; these data were previously reported by the Molecular Mechanisms in Malignant Lymphomas Network Project (MMMLNP).^{13 (link)}

Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., Xu W., Tan B., Goldschmidt N., Iqbal J., Vose J., Bast M., Fu K., Weisenburger D.D., Greiner T.C., Armitage J.O., Kyle A., May L., Gascoyne R.D., Connors J.M., Troen G., Holte H., Kvaloy S., Dierickx D., Verhoef G., Delabie J., Smeland E.B., Jares P., Martinez A., Lopez-Guillermo A., Montserrat E., Campo E., Braziel R.M., Miller T.P., Rimsza L.M., Cook J.R., Pohlman B., Sweetenham J., Tubbs R.R., Fisher R.I., Hartmann E., Rosenwald A., Ott G., Muller-Hermelink H.K., Wrench D., Lister T.A., Jaffe E.S., Wilson W.H., Chan W.C, & Staudt L.M. (2008). Stromal Gene Signatures in Large-B-Cell Lymphomas. The New England journal of medicine, 359(22), 2313-2323.

Publication 2008

Anthracyclines Biopsy DDIT3 protein, human Diagnosis Diffuse Large B-Cell Lymphoma Ethics Committees, Research Lymphoma Neoplasms Patients Pharmacotherapy Rituximab Survivors Treatment Protocols

DLBCL Molecular Profiling Protocol

Cited 15 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012

Anthracyclines Biopsy Combination Drug Therapy DDIT3 protein, human Ethics Committees, Research Freezing Malignant Neoplasms Neoplasms Patients Rituxan Tissues Treatment Protocols Woman

Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer

Cited 15 times

From April 2001 through March 2004, we randomly assigned 3222 women with HER2-positive, invasive, high-risk, node-negative or node-positive adenocarcinoma (stage T1, T2, or T3) from 41 countries to receive a standard adjuvant anthracycline–taxane chemotherapy regimen, the same regimen plus trastuzumab, or a new non-anthracycline, trastuzumab-based regimen (Fig. 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). Specific demographic and clinical characteristics of patients were similar in the three study groups (Table 1). The HER2-positive status of all tumors was confirmed with the use of fluorescence in situ hybridization (PathVision, Abbott) before randomization.
In the first group, women received standard therapy with doxorubicin (60 mg per square meter) and cyclophosphamide (600 mg per square meter) every 3 weeks for four cycles, followed by docetaxel (100 mg per square meter) every 3 weeks for four doses (AC-T). In the second group, patients received AC-T plus trastuzumab, beginning with the first dose of docetaxel and continuing for 1 year (AC-T plus trastuzumab). In the third group, patients received docetaxel (75 mg per square meter) plus carboplatin (area under the curve, 6 mg per milliliter per minute), given every 3 weeks for six cycles concurrently with trastuzumab, followed by trastuzumab for an additional 34 weeks (TCH). In the two trastuzumab-containing regimens, trastuzumab was initially administered at a dose of 4 mg per kilogram of body weight, followed by 2 mg per kilogram per week during chemotherapy and then 6 mg per kilogram every 3 weeks to complete 1 year of trastuzumab treatment. Hematopoietic growth factors were used at the discretion of treating physicians.
The institutional review board at each institution approved the study. All patients provided written informed consent.

Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M.A., Riva A, & Crown J. (2011). Adjuvant Trastuzumab in HER2-Positive Breast Cancer. The New England Journal of Medicine, 365(14), 1273-1283.

Publication 2011

Adenocarcinoma Anthracyclines Body Weight Carboplatin Chemotherapy, Adjuvant Cyclophosphamide Docetaxel Doxorubicin ERBB2 protein, human Ethics Committees, Research Fluorescent in Situ Hybridization Hematopoietic Cell Growth Factors Neoplasms Patients Pharmacotherapy Physicians taxane Trastuzumab Treatment Protocols Woman

Most recents protocols related to «Anthracyclines»

Breast Cancer Cell Line Cultivation

The murine and human breast carcinoma cell lines 4T1 and MCF-7, respectively, were acquired from the Chinese Academy of Sciences Shanghai Institute for Biological Sciences Cell Resource Center and incubated in RPMI 1640 and DMEM media. The anthracycline drug-resistant human breast carcinoma cell line, MCF-7/ADR, has been generously contributed by Professor Jianhua Xu, College of Pharmacy, Fujian Medical University, and cultivated in RPMI 1640 media. Moreover, the two media were enriched with 10% FBS, penicillin (100 U/mL), and streptomycin (100 mg/mL). Cell line culture was incubated at 37°C in a humidified setting with 5% CO₂.

Chen Z., Liu Z., Zhang Q., Huang S., Zhang Z., Feng X., Zeng L., Lin D., Wang L, & Song H. (2023). Hypoxia-ameliorated photothermal manganese dioxide nanoplatform for reversing doxorubicin resistance. Frontiers in Pharmacology, 14, 1133011.

Full text: Click here

Publication 2023

Anthracyclines Cell Culture Techniques Cells Chinese Homo sapiens MCF-7 Cells Mus Penicillins Pharmaceutical Preparations Streptomycin

Non-Inferiority Cardiac Surveillance in HER2+ Breast Cancer

The proportion of patients who develop a cardiac event at 12 months will be estimated together with an exact 95% confidence interval. Based upon our preliminary data of early-stage HER2-positive patients treated with non-anthracycline trastuzumab-based regimens, the estimated cardiac event rate is 1.2% (95% CI 0.1–4.1%) [21 ]. The null hypothesis of the current study is that a reduced cardiotoxicity surveillance strategy is non-inferior to routine standard-of-care surveillance by a prespecified margin in the cardiac event rate of 2.9%. This non-inferiority margin corresponds to the difference between the observed cardiac event rate from our preliminary data and the upper bound of the 95% confidence interval. With 190 patients, we will have 84% power to reject the null hypothesis using a one-sided exact test with a significance level of 0.052. We will reject the null hypothesis if no more than 3 participants develop a cardiac event. If 4 or more cardiac events are observed during any point in the trial, the study will stop.

Yu A.F., Dang C.T., Jorgensen J., Moskowitz C.S., DeFusco P., Oligino E., Oeffinger K.C., Liu J.E, & Steingart R.M. (2023). Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. Cardio-oncology, 9, 13.

Full text: Click here

Publication 2023

Anthracyclines Cardiac Events Cardiotoxicity ERBB2 protein, human Patients Rate, Heart Trastuzumab Treatment Protocols

Reduced Cardiac Monitoring in HER2+ Breast Cancer

This is a single-arm prospective trial (ClinicalTrials.gov Identifier: NCT03983382) with a primary objective to evaluate the cardiac safety of a reduced cardiotoxicity surveillance strategy (every 6 months) in patients with HER2-positive breast cancer treated with a non-anthracycline HER2-targeted treatment regimen. Secondary objectives include the following: 1) to measure the change in LVEF and global longitudinal strain (GLS) after 6 and 12 months of treatment compared to baseline; 2) to estimate the incidence of asymptomatic LVEF decline; 3) to estimate the incidence of early interruption of HER2-targeted treatment; and 4) to determine feasibility of a reduced cardiotoxicity surveillance strategy.

Full text: Click here

Publication 2023

Anthracyclines Cardiotoxicity erbb2 Gene Heart Malignant Neoplasm of Breast Patients Safety Treatment Protocols

Cardiac Safety in HER2+ Breast Cancer

The study will be conducted in HER2-positive breast cancer patients (stage I-IV) receiving a non-anthracycline-based chemotherapy regimen in combination with a HER2-targeted agent (e.g. trastuzumab, pertuzumab, or ado-trastuzumab emtansine). The primary exclusion criteria are: (1) prior treatment with anthracyclines or HER2-targeted therapy; (2) baseline LVEF < 53% (or institutional lower limit of normal); (3) systolic or diastolic blood pressure ≥ 160 mmHg or ≥ 90 mmHg, respectively; and (4) history of heart failure, cardiomyopathy, or other significant CVD associated with increased cardiotoxicity risk (e.g. atrial fibrillation, atherosclerotic cardiovascular disease, significant valvular heart disease, etc.). Following approval by the primary medical oncologist, written informed consent will be obtained from each patient prior to study enrollment. The inclusion and exclusion criteria of this study are presented in Table 1.Table 1

Main eligibility criteria

Inclusion criteria	Exclusion criteria
1. Female 2. Age ≥ 18 years 3. Pathologically confirmed HER2-positive invasive breast carcinoma (stage I-IV) 4. Anticipated treatment with HER2-targeted therapy for ≥ 12 months 5. Normal LV systolic function (LVEF ≥ institutional lower limit of normal) 6. Willing and able to provide written informed consent and comply with the requirements of the protocol	1. Anticipated treatment with anthracycline chemotherapy 2. Prior treatment with anthracycline chemotherapy 3. History of cardiomyopathy, heart failure, or other clinically significant cardiovascular disease 4. Uncontrolled hypertension, defined as a systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg

Inclusion criteria

Exclusion criteria

1. Female

2. Age ≥ 18 years

3. Pathologically confirmed HER2-positive invasive breast carcinoma (stage I-IV)

4. Anticipated treatment with HER2-targeted therapy for ≥ 12 months

5. Normal LV systolic function (LVEF ≥ institutional lower limit of normal)

6. Willing and able to provide written informed consent and comply with the requirements of the protocol

1. Anticipated treatment with anthracycline chemotherapy

2. Prior treatment with anthracycline chemotherapy

3. History of cardiomyopathy, heart failure, or other clinically significant cardiovascular disease

4. Uncontrolled hypertension, defined as a systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg

Full text: Click here

Publication 2023

Ado-Trastuzumab Emtansine Anthracyclines Atherosclerosis Atrial Fibrillation Breast Carcinoma Cardiomyopathies Cardiotoxicity Cardiovascular System Combination Drug Therapy Congestive Heart Failure Eligibility Determination erbb2 Gene High Blood Pressures Malignant Neoplasm of Breast Oncologists Patients pertuzumab Pressure, Diastolic Systole Systolic Pressure Trastuzumab Treatment Protocols Valve Disease, Heart

Multivariable Model for HER2+ AGC Prognosis

The objective was to develop and externally validate a multivariable model to stratify patients with HER2+ AGA according to PFS/OS. Outcome variables were PFS and OS defined as the time in months between initiation of first-line chemotherapy and progression or death, respectively, censoring subjects alive at last follow-up.
Candidate predictors were selected after an exhaustive literature search, and after consultation with experts from the participating centres. No data-driven method was used in the final selection of variables.²¹ All covariates had to be available at the start of treatment (e.g. the primary tumour surgery variable was only considered when subjects had been exposed before the start of first-line treatment). The covariates considered in this model were age, Eastern Cooperative Oncology Group performance status (ECOG PS; ⩾2 versus 0–1), primary tumour location (oesophagus, GEJ, stomach), HER2 expression level (IHC 2+/FISH+ versus IHC 3+), Lauren subtype (intestinal versus diffuse and mixed), signet ring cells, histological grade (1, 2, versus 3), overall tumour burden (stratified into four categories, Table 1), neutrophil-to-lymphocyte ratio (NLR; non-linear, continuous), albumin, carcinoembryonic antigen, CEA (non-linear, continuous), primary tumour surgery, chemotherapy regimen (anthracycline-based triplets, carboplatin–5-fluorouracil, carboplatin–capecitabine, cisplatin–5-fluorouracil, docetaxel-containing regimens, 5-fluorouracil/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, others). Criteria to stratify the overall tumour burden (Table 1) have been used previously by our group.²² The OS analyses stratified by this variable on the entire cohort, as well as the Manchester series, suggest that these criteria are valid (Supplemental Annex Figure 1).

Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W, & Gallego J. (2023). The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology, 15, 17588359231157641.

Publication 2023

Albumins Anthracyclines Capecitabine Carboplatin Carcinoembryonic Antigen Cells Cisplatin Disease Progression Docetaxel Electrocorticography ERBB2 protein, human Esophagus Fishes Fluorouracil Intestines Lymphocyte Neoplasms Neoplasms by Site Neutrophil Operative Surgical Procedures Oxaliplatin Patients Pharmacotherapy Stomach Treatment Protocols Triplets Tumor Burden XELOX

Top products related to «Anthracyclines»

Sas version 9 by SAS Institute

Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India

SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.

Synergy ht by Agilent Technologies

Sourced in United States, Germany, United Kingdom, Italy, Switzerland, Portugal, Japan, China, France, Australia, Holy See (Vatican City State), Spain

The Synergy HT is a multi-mode microplate reader from Agilent Technologies. It is designed to perform absorbance, fluorescence, and luminescence measurements on microplates. The Synergy HT provides reliable data for a wide range of applications, including cell-based assays, ELISA, and other microplate-based experiments.

Celltiter glo by Promega

Sourced in United States, United Kingdom, Germany, France, Switzerland, Italy, Japan, Belgium, Australia, China

CellTiter-Glo is a cell viability assay that quantifies the amount of ATP present in metabolically active cells. It provides a luminescent readout proportional to the amount of ATP, which is an indicator of the presence of viable cells.

Stata 16 by StataCorp

Sourced in United States, United Kingdom, Austria

Stata 16 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of tools and functionalities for researchers, academics, and professionals working with quantitative data. Stata 16 offers advanced statistical methods, data manipulation capabilities, and flexible programming features to support various analytical tasks.

Methyl methanesulfonate by Merck Group

Sourced in United States, Germany, France, Spain

Methyl methanesulfonate is a colorless, viscous liquid chemical compound. It is commonly used as a research tool in laboratory settings.

Dimethyl sulfoxide (dmso) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh

DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.

Cobas e601 immunoassay analyzer by Roche

Sourced in Japan

The Cobas e601 is an automated immunoassay analyzer designed for performing various diagnostic tests. It is capable of processing a range of immunoassay tests, which are used to detect and measure specific proteins, hormones, or other analytes in patient samples. The Cobas e601 is intended for use in clinical laboratories to aid in the diagnosis and monitoring of various medical conditions.

4.5k snp genotype data set by Illumina

The 4.5K SNP genotype data set is a comprehensive collection of genomic data that covers over 4,500 single nucleotide polymorphisms (SNPs). This dataset provides researchers with a detailed snapshot of genetic variation within a population or sample. The core function of this data set is to enable efficient and cost-effective genetic analysis for a wide range of applications, including population genetics, genome-wide association studies, and genetic mapping.

Fetal bovine serum (fbs) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal

Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

Confocal laser scanning microscope by Zeiss

Sourced in Germany, United States, China, Japan, United Kingdom

The Confocal laser scanning microscope is an advanced imaging system that utilizes a focused laser beam and a series of pinholes to capture high-resolution, three-dimensional images of samples. It provides optical sectioning capabilities, allowing for the visualization of specific focal planes within a specimen.

More about "Anthracyclines"

Anthracyclines are a class of powerful chemotherapeutic agents derived from the Streptomyces peucetius bacterium.
These potent anti-cancer drugs work by intercalating into DNA and inhibiting topoisomerase II, leading to cell death.
Commonly used to treat a wide range of cancers, including leukemia, lymphoma, and solid tumors, anthracyclines are a mainstay of many chemotherapy regimens.
However, their use can be limited by the risk of serious side effects, such as cardiotoxicity.
Researchers can leverage cutting-edge tools like PubCompare.ai to streamline their anthracycline-related studies.
This AI-driven platform empowers reproducibility and accuracy by helping scientists easily locate relevant protocols from literature, preprints, and patents.
Leveraging the power of AI-powered comparisons, researchers can identify the optimal protocols and products for their specific research needs, optimizing their studies and driving scientific progress forward.
In addition to anthracyclines, researchers may also utilize a variety of other cutting-edge tools and technologies in their work.
These can include statistical software like SAS version 9.4 and Stata 16, cell viability assays like Synergy HT and CellTiter-Glo, and advanced imaging techniques like confocal laser scanning microscopy.
Researchers may also work with common laboratory reagents and materials, such as DMSO, FBS, and Methyl methanesulfonate, as well as high-throughput genotyping platforms like the 4.5K SNP genotype data set and immunoassay analyzers like the Cobas e601.
By combining their expertise in anthracyclines with the latest tools and technologies, researchers can push the boundaries of cancer research, working towards more effective treatments and improved patient outcomes.